Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.94 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.94 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.94 |
| ▸ | HTR2A | P28223 | 1/20 | 0.94 |
| ▸ | HTR2C | P28335 | 1/20 | 0.94 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.94 |
| ▸ | HRH1 | P35367 | 1/20 | 0.94 |
| ▸ | DRD3 | P35462 | 1/20 | 0.94 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.94 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.94 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.94 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.94 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.60 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.60 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.60 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.60 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valproic Acid SCHEMBL2275 | 0.97 | CHRM1 (1.00) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL1330837 | 0.97 | CHRM1 (1.00) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL140241 | 0.97 | CHRM1 (1.00) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL1311803 | 0.94 | CHRM1 (0.94) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL69795 | 0.94 | CHRM1 (0.94) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL139238 | 0.94 | CHRM1 (0.94) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL7579608 | 0.94 | CHRM1 (0.94) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL6910916 | 0.94 | CHRM1 (0.94) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL2054191 | 0.94 | CHRM1 (0.94) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL21378840 | 0.94 | CHRM1 (0.94) | CHRM1AKR1A1CHRM3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100062114-A1 | NUTRACEUTICAL COMPOSITION FOR IMPROVING FOOTPAD & COAT AND SKIN QUALITY IN PETS | DSM IP ASSETS B.V. (NL) | 2010-03-11 | — | — | US | claimed |
| US-20090182036-A1 | ANIMAL FOOD COMPOSITION COMPRISING GENISTEIN AND POLYUNSATURATED FATTY ACIDS | DSM IP ASSETS B.V. (NL) | 2009-07-16 | — | — | US | claimed |
| EP-2015644-A1 | ANIMAL FOOD COMPOSITION COMPRISING GENISTEIN AND POLYUNSATURATED FATTY ACIDS | DSMIP Assets B.V. (NL) | 2009-01-21 | — | — | EP | claimed |
| EP-1901613-A1 | NUTRACEUTICAL COMPOSITION FOR IMPROVING FOOTPAD&COAT AND SKIN QUALITY IN PETS | DSMIP Assets B.V. (NL) | 2008-03-26 | — | — | EP | claimed |
| WO-2007128461-A1 | ANIMAL FOOD COMPOSITION COMPRISING GENISTEIN AND POLYUNSATURATED FATTY ACIDS | DSM IP ASSETS B.V. (NL) | 2007-11-15 | — | — | WO | claimed |
| WO-2007006471-A1 | NUTRACEUTICAL COMPOSITION FOR IMPROVING FOOTPAD & COAT AND SKIN QUALITY IN PETS | DSM IP ASSETS B.V. (NL) | 2007-01-18 | — | — | WO | claimed |
| JP-5148140-A | — | — | None | — | — | JP | disclosed |
| EP-3042718-A1 | DEVICE FOR SOLUBILIZING, SEPARATING, REMOVING AND REACTING CARBOXYLIC ACIDS IN OILS, FATS, AQUEOUS OR ORGANIC SOLUTIONS BY MEANS OF MICRO- OR NANOEMULSIFICATION | Dietz, Ulrich (DE) | 2016-07-13 | — | — | EP | disclosed |
| US-9381213-B2 | Antiviral and immune stimulant pharmaceutical composition | SINNEX MUSZAKI FEJLESZTO ES TANACSADO KFT (HU) | 2016-07-05 | — | — | US | disclosed |
| US-20160122686-A1 | DEVICE AND METHOD FOR SOLUBILIZING, SEPARATING, REMOVING AND REACTING CARBOXYLIC ACIDS IN OILS, FATS, AQUEOUS OR ORGANIC SOLUTIONS BY MEANS OF MICRO-OR NANOEMULSIFICATION | DIETZ ULRICH (DE) | 2016-05-05 | — | — | US | disclosed |
| EP-2585420-B1 | METHOD FOR SOLUBILIZING, SEPARATING, REMOVING AND REACTING CARBOXYLIC ACIDS IN OILS, FATS, AQUEOUS OR ORGANIC SOLUTIONS BY MEANS OF MICRO- OR NANOEMULSIFICATION | DIETZ ULRICH (DE) | 2016-04-06 | — | — | EP | disclosed |
| US-9127233-B2 | Device and method for solubilizing, separating, removing and reacting carboxylic acids in oils, fats, aqueous or organic solutions by means of micro-or nanoemulsification | Dietz, Ulrich (DE) | 2015-09-08 | — | — | US | disclosed |
| EP-2585420-A2 | DEVICE AND METHOD FOR SOLUBILIZING, SEPARATING, REMOVING AND REACTING CARBOXYLIC ACIDS IN OILS, FATS, AQUEOUS OR ORGANIC SOLUTIONS BY MEANS OF MICRO- OR NANOEMULSIFICATION | Dietz, Ulrich (DE) | 2013-05-01 | — | — | EP | disclosed |
| EP-1830861-A2 | ANTIVIRAL AND IMMUNOSTIMULATING MARINE FISH OIL COMPOSITION | Sinnex Müszaki Fejlesztö S Tanacsado KFT (HU) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006059169-A2 | ANTIVIRAL AND IMMUNOSTIMULATING MARINE FISH OIL COMPOSITION | SINNEX MÜSZAKI FEJLESZTÖ ÉS TANÁCSADÓ KFT (HU) | 2006-06-08 | — | — | WO | disclosed |
| US-7034058-B2 | Anti-tumor pharmaceutical composition comprising N-vanillyl fatty acid amide | KUREHA CORPORATION (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20040110844-A1 | Anti-tumor pharmaceutical composition comprising N-vanillyl fatty acid amide | KUREHA CHEMICAL INDUSTRY COMPANY, LIMITED | 2004-06-10 | — | — | US | disclosed |
| JP-H05148140-A | MALARIA-TREATING MEDICINE | NIPPON OIL & FATS CO LTD | 1993-06-15 | — | — | JP | disclosed |
| US-4673684-A | Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient | TERUMO CORPORATION (JP) | 1987-06-16 | — | — | US | disclosed |
| EP-0157420-A2 | Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION (JP) | 1985-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110844-A1 | Anti-tumor pharmaceutical composition comprising N-vanillyl fatty acid amide | ELOVL1, TRPV1, ELOVL5 | CHRM1 1820/4885AKR1A1 2966/4885CHRM3 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.